ARCT
Arcturus Therapeutics Holdings Inc

5,029
Loading...
Loading...
News
all
press releases
Should You Buy Arcturus Therapeutics (ARCT) After Golden Cross?
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
Zacks·12d ago
News Placeholder
More News
News Placeholder
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +69.37% and +20.84%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Beats Revenue Estimates
Clearside Biomedical (CLSD) delivered earnings and revenue surprises of +50.00% and +87.07%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Insmed (INSM) Reports Q2 Loss, Beats Revenue Estimates
Insmed (INSM) delivered earnings and revenue surprises of -30.77% and +3.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Lags Revenue Estimates
Tango Therapeutics (TNGX) delivered earnings and revenue surprises of 0.00% and -48.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Wall Street Analysts Think Arcturus Therapeutics (ARCT) Could Surge 371.35%: Read This Before Placing a Bet
Zacks·3mo ago
News Placeholder
Wall Street Analysts Believe Arcturus Therapeutics (ARCT) Could Rally 503.6%: Here's is How to Trade
Zacks·4mo ago
News Placeholder
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates
Zacks·4mo ago
News Placeholder
2 Growth Stocks to Buy Now With 367% to 410% Upside
Strong, innovative pipelines make these two biotech firms smart buys now.
barchart.com·6mo ago
News Placeholder
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025
Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities...
Business Wire·7mo ago

Latest ARCT News

View

Advertisement. Remove ads.

Advertisement. Remove ads.